Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Increase in Inhaled Corticosteroid Dose vs Triple Therapy in T2-high Asthma Patients Who Remain Uncontrolled With Medium Dose Inhaled Corticosteroids/Long-acting β2 Adrenergic Combination: a Real-life Study. TRICORDA Study

NCT05919394 is registered in ClinicalTrials.gov with Galaxia Empírica as lead sponsor.

NCT NCT05919394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05919394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Increase in Inhaled Corticosteroid Dose vs Triple Therapy in T2-high Asthma Patients Who Remain Uncontrolled With Medium Dose Inhaled Corticosteroids/Long-acting β2 Adrenergic Combination: a Real-life Study. TRICORDA Study
Lead sponsor
Galaxia Empírica
Phase
Phase 4
Overall status
Withdrawn
Start date
June 1, 2023
Completion date
November 14, 2024
Enrollment
0 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

asthma